Abstract
The present study was carried out with a view to enhance dissolution rate of poorly water-soluble drug glipizide (GZ) (BCS class II) using polyethylene glycol (PEG) 6000, PEG 8000 and poloxamer (PXM) 188 as carriers. Solid dispersions (SDs) were prepared by melting method using different ratios of glipizide to carriers. Phase solubility study was conducted to evaluate the effect of carrier on aqueous solubility of glipizide. SD was optimized by drug content estimation and in vitro dissolution study and optimised SD was subjected to bulk characterization, Scanning electron microscopy (SEM), Fourier transformation infrared spectroscopy (FTIR), Differential scanning calorimetry (DSC) and X-ray diffraction study (XRD). Preclinical study was performed in mice to study the decrease in blood glucose level from prepared SD compared with pure drug. Due to high solubility and drug release, PXM 188 in weight ratio of 1:2 was optimized. Decrease in blood glucose level in mice from SD was significantly higher (p < 0.05) compared to pure glipizide. Thus, solid dispersion technique can be successfully used for the improvement of the dissolution profile of GZ.
Keywords: Solid dispersion, Dissolution profile, Preclinical study
Current Drug Delivery
Title:Formulation and In Vivo Hypoglycemic Effect of Glipizide Solid Dispersion
Volume: 9 Issue: 4
Author(s): Gayatri C. Patel, Khusman V. Asodaria, Hetal P. Patel and Dinesh R. Shah
Affiliation:
Keywords: Solid dispersion, Dissolution profile, Preclinical study
Abstract: The present study was carried out with a view to enhance dissolution rate of poorly water-soluble drug glipizide (GZ) (BCS class II) using polyethylene glycol (PEG) 6000, PEG 8000 and poloxamer (PXM) 188 as carriers. Solid dispersions (SDs) were prepared by melting method using different ratios of glipizide to carriers. Phase solubility study was conducted to evaluate the effect of carrier on aqueous solubility of glipizide. SD was optimized by drug content estimation and in vitro dissolution study and optimised SD was subjected to bulk characterization, Scanning electron microscopy (SEM), Fourier transformation infrared spectroscopy (FTIR), Differential scanning calorimetry (DSC) and X-ray diffraction study (XRD). Preclinical study was performed in mice to study the decrease in blood glucose level from prepared SD compared with pure drug. Due to high solubility and drug release, PXM 188 in weight ratio of 1:2 was optimized. Decrease in blood glucose level in mice from SD was significantly higher (p < 0.05) compared to pure glipizide. Thus, solid dispersion technique can be successfully used for the improvement of the dissolution profile of GZ.
Export Options
About this article
Cite this article as:
C. Patel Gayatri, V. Asodaria Khusman, P. Patel Hetal and R. Shah Dinesh, Formulation and In Vivo Hypoglycemic Effect of Glipizide Solid Dispersion, Current Drug Delivery 2012; 9 (4) . https://dx.doi.org/10.2174/156720112801323134
DOI https://dx.doi.org/10.2174/156720112801323134 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Advances in the Treatment of Neurodegenerative Disorders Employing Nanoparticles
Recent Patents on Drug Delivery & Formulation Reactive Oxygen Species in Vascular Wall
Cardiovascular & Hematological Disorders-Drug Targets Pleiotropic Effects of Rimonabant: Clinical Implications
Current Pharmaceutical Design When Cells Become a Drug. Endothelial Progenitor Cells for Cardiovascular Therapy: Aims and Reality
Recent Patents on Cardiovascular Drug Discovery Relationships Between Metformin, Paraoxonase-1 and the Chemokine (C-C Motif) Ligand 2
Current Clinical Pharmacology Editorial from Editor-in-Chief: Hypoglossal Nerve Stimulation: An Emerging and Futuristic Therapy for Obstructive Sleep Apnea
Current Respiratory Medicine Reviews L-carnosine and its Derivatives as New Therapeutic Agents for the Prevention and Treatment of Vascular Complications of Diabetes
Current Medicinal Chemistry Epigenetic Variation and Customising Nutritional Intervention
Current Pharmacogenomics and Personalized Medicine Novel Treatments in Diabetic Nephropathy
Current Hypertension Reviews ESVS Guidelines: Section A - Prevention in Patients with Carotid Stenosis
Current Vascular Pharmacology The Role of Polyunsaturated Fatty Acids (PUFA) in the Treatment of Dyslipidemias
Current Pharmaceutical Design Associations of Plasma BACE1 Level and BACE1 C786G Gene Polymorphism with Cognitive Functions in Patients with Type 2 Diabetes: A Cross- Sectional Study
Current Alzheimer Research The Management of the Infected Diabetic Foot
Current Diabetes Reviews Recent Insights into the Role of Prostanoids in Atherosclerotic Vascular Disease
Current Vascular Pharmacology Pharmacotherapy in Type 2 Diabetes: A Functional Schema for Drug Classification
Current Diabetes Reviews MicroRNAs as Biomarkers in Hypertrophic Cardiomyopathy: Current State of the Art
Current Medicinal Chemistry Pharmacotherapy of Mixed Dyslipidemia in the Metabolic Syndrome
Current Clinical Pharmacology Large Artery Stiffness and Antihypertensive Agents
Current Pharmaceutical Design A Neuroinformatics Study Describing Molecular Interaction of Cisplatin with Acetylcholinesterase: A Plausible Cause for Anticancer Drug Induced Neurotoxicity
CNS & Neurological Disorders - Drug Targets Nitric Oxide and Major Depressive Disorder: Pathophysiology and Treatment Implications
Current Molecular Medicine